Feature         Mutant TP53 (%)               95% CI              OddsRatio

Age ≤45yrs            0/10                                    0.027-2.526          0.259 >45yrs            6/20 (66.6%)

Rural               5/24 (20.83%)                    0.124-13.967 1.316 Urban             1/6 (16.67%)

Lymph node/s involved Yes                 5/6 (83.3%)                         0.091-11.028        1.00 No                  1/6 (16.7%)

Clinical Tumor stage II                   1/10 (10%)                            0.033-3.327         3.327               III                  5/20 (25%)

Table 5: Association of TP53 gene mutation with Clinico-epidemiological features of gastric adenocarcinoma patients of Kashmir (n=30).